Marea Therapeutics at Jefferies Global Healthcare Conference: two shots at crowded markets
Marea Therapeutics showcased a two-program strategy at the Jefferies Global Healthcare Conference, emphasizing clinical data, human genetics, and a strengthened balance sheet. CEO Josh Lehrer highlighted the company's lead assets with promising early results, though larger studies are required to confirm their profiles. The merger with Lisata Therapeutics and a PIPE financing extend Marea's cash runway through mid-2028.
MAR001, targeting severe hypertriglyceridemia, showed triglyceride reductions comparable to ApoC-III inhibitors without a glucose penalty. MAR002, for acromegaly, produced the largest IGF-1 drop in early testing, with no drug-related safety signals. The company aims to capture markets worth $10 billion for severe hypertriglyceridemia and $1.4 billion for acromegaly.
Management stated that the next step is to confirm early data in larger patient studies before advancing to phase III trials.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.